US Pharma MarketingThe post Ollin Biosciences secures $330m to fund Phase III OLN324 trials appeared first on Clinical Trials Arena.
Ollin Biosciences secures $330m to fund Phase III OLN324 trials
Ollin Biosciences has completed a $330m Series B financing round to support the global Phase III development of its lead candidate OLN324 for the treatment of DME and wAMD. The global Phase III trials of OLN324 in DME and wAMD will be launched in the second half of 2026. The JADE study showed that OLN324 produced faster and greater improvements in retinal anatomy than faricimab in DME and wAMD. Credit: Komsan Loonprom / Shutterstock.com. Ollin Biosciences has completed a $330m Series B financing round to support the global Phase III development of its lead candidate OLN324 for the treatment of…
Ollin Biosciences has completed a $330m Series B financing round to support the global Phase III development of its lead candidate OLN324 for the treatment of DME and wAMD.
Source: Clinical Trials Arena